Department of Physiotherapy, Monash University, Melbourne, Australia.
Monash Lung and Sleep, Monash Health, Melbourne, Australia.
Cochrane Database Syst Rev. 2022 Aug 22;8(8):CD013485. doi: 10.1002/14651858.CD013485.pub2.
Asthma is a respiratory disease characterised by variable airflow limitation and the presence of respiratory symptoms including wheeze, chest tightness, cough and/or dyspnoea. Exercise training is beneficial for people with asthma; however, the response to conventional models of pulmonary rehabilitation is less clear.
To evaluate, in adults with asthma, the effectiveness of pulmonary rehabilitation compared to usual care on exercise performance, asthma control, and quality of life (co-primary outcomes), incidence of severe asthma exacerbations/hospitalisations, mental health, muscle strength, physical activity levels, inflammatory biomarkers, and adverse events.
We identified studies from the Cochrane Airways Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform, from their inception to May 2021, as well as the reference lists of all primary studies and review articles.
We included randomised controlled trials in which pulmonary rehabilitation was compared to usual care in adults with asthma. Pulmonary rehabilitation must have included a minimum of four weeks (or eight sessions) aerobic training and education or self-management. Co-interventions were permitted; however, exercise training alone was not. DATA COLLECTION AND ANALYSIS: Following the use of Cochrane's Screen4Me workflow, two review authors independently screened and selected trials for inclusion, extracted study characteristics and outcome data, and assessed risk of bias using the Cochrane risk of bias tool. We contacted study authors to retrieve missing data. We calculated between-group effects via mean differences (MD) or standardised mean differences (SMD) using a random-effects model. We evaluated the certainty of evidence using GRADE methodology.
We included 10 studies involving 894 participants (range 24 to 412 participants (n = 2 studies involving n > 100, one contributing to meta-analysis), mean age range 27 to 54 years). We identified one ongoing study and three studies awaiting classification. One study was synthesised narratively, and another involved participants specifically with asthma-COPD overlap. Most programmes were outpatient-based, lasting from three to four weeks (inpatient) or eight to 12 weeks (outpatient). Education or self-management components included breathing retraining and relaxation, nutritional advice and psychological counselling. One programme was specifically tailored for people with severe asthma. Pulmonary rehabilitation compared to usual care may increase maximal oxygen uptake (VO max) after programme completion, but the evidence is very uncertain for data derived using mL/kg/min (MD between groups of 3.63 mL/kg/min, 95% confidence interval (CI) 1.48 to 5.77; 3 studies; n = 129) and uncertain for data derived from % predicted VO max (MD 14.88%, 95% CI 9.66 to 20.1%; 2 studies; n = 60). The evidence is very uncertain about the effects of pulmonary rehabilitation compared to usual care on incremental shuttle walk test distance (MD between groups 74.0 metres, 95% CI 26.4 to 121.4; 1 study; n = 30). Pulmonary rehabilitation may have little to no effect on VOmax at longer-term follow up (9 to 12 months), but the evidence is very uncertain (MD -0.69 mL/kg/min, 95% CI -4.79 to 3.42; I = 49%; 3 studies; n = 66). Pulmonary rehabilitation likely improves functional exercise capacity as measured by 6-minute walk distance, with MD between groups after programme completion of 79.8 metres (95% CI 66.5 to 93.1; 5 studies; n = 529; moderate certainty evidence). This magnitude of mean change exceeds the minimally clinically important difference (MCID) threshold for people with chronic respiratory disease. The evidence is very uncertain about the longer-term effects one year after pulmonary rehabilitation for this outcome (MD 52.29 metres, 95% CI 0.7 to 103.88; 2 studies; n = 42). Pulmonary rehabilitation may result in a small improvement in asthma control compared to usual care as measured by Asthma Control Questionnaire (ACQ), with an MD between groups of -0.46 (95% CI -0.76 to -0.17; 2 studies; n = 93; low certainty evidence); however, data derived from the Asthma Control Test were very uncertain (MD between groups 3.34, 95% CI -2.32 to 9.01; 2 studies; n = 442). The ACQ finding approximates the MCID of 0.5 points. Pulmonary rehabilitation results in little to no difference in asthma control as measured by ACQ at nine to 12 months follow-up (MD 0.09, 95% CI -0.35 to 0.53; 2 studies; n = 48; low certainty evidence). Pulmonary rehabilitation likely results in a large improvement in quality of life as assessed by the St George's Respiratory Questionnaire (SGRQ) total score (MD -18.51, 95% CI -20.77 to -16.25; 2 studies; n = 440; moderate certainty evidence), with this magnitude of change exceeding the MCID. However, pulmonary rehabilitation may have little to no effect on Asthma Quality of Life Questionnaire (AQLQ) total scores, with the evidence being very uncertain (MD 0.87, 95% CI -0.13 to 1.86; 2 studies; n = 442). Longer-term follow-up data suggested improvements in quality of life may occur as measured by SGRQ (MD -13.4, 95% CI -15.93 to -10.88; 2 studies; n = 430) but not AQLQ (MD 0.58, 95% CI -0.23 to 1.38; 2 studies; n = 435); however, the evidence is very uncertain. One study reported no difference between groups in the proportion of participants who experienced an asthma exacerbation during the intervention period. Data from one study suggest adverse events attributable to the intervention are rare. Overall risk of bias was most commonly impacted by performance bias attributed to a lack of participant blinding to knowledge of the intervention. This is inherently challenging to overcome in rehabilitation studies. AUTHORS' CONCLUSIONS: Moderate certainty evidence shows that pulmonary rehabilitation is probably associated with clinically meaningful improvements in functional exercise capacity and quality of life upon programme completion in adults with asthma. The certainty of evidence relating to maximal exercise capacity was very low to low. Pulmonary rehabilitation appears to confer minimal effect on asthma control, although the certainty of evidence is very low to low. Unclear reporting of study methods and small sample sizes limits our certainty in the overall body of evidence, whilst heterogenous study designs and interventions likely contribute to inconsistent findings across clinical outcomes and studies. There remains considerable scope for future research.
哮喘是一种以气流受限的可变性和呼吸症状(包括喘息、胸闷、咳嗽和/或呼吸困难)为特征的呼吸系统疾病。运动训练对哮喘患者有益;然而,常规肺康复模型的反应不太清楚。
评估在哮喘患者中,与常规护理相比,肺康复在运动表现、哮喘控制和生活质量(共同主要结局)、严重哮喘恶化/住院的发生率、心理健康、肌肉力量、身体活动水平、炎症生物标志物和不良事件方面的有效性。
我们从 Cochrane 气道试验登记处、Cochrane 中心对照试验注册库(CENTRAL)、MEDLINE、Embase、ClinicalTrials.gov 和世界卫生组织国际临床试验注册平台检索了研究,检索时间从成立到 2021 年 5 月,以及所有初级研究和综述文章的参考文献列表。
我们纳入了将肺康复与哮喘成人的常规护理进行比较的随机对照试验。肺康复必须包括至少四周(或八节)的有氧运动训练和教育或自我管理。允许联合干预;然而,单独的运动训练是不允许的。
在使用 Cochrane 的 Screen4Me 工作流程后,两名综述作者独立筛选并选择纳入的试验,提取研究特征和结局数据,并使用 Cochrane 偏倚风险工具评估偏倚风险。我们联系了研究作者以获取缺失的数据。我们使用随机效应模型通过均数差(MD)或标准化均数差(SMD)计算组间效应。我们使用 GRADE 方法评估证据的确定性。
我们纳入了 10 项研究,涉及 894 名参与者(范围为 24 至 412 名参与者(n = 2 项研究涉及 n > 100,一项对 meta 分析有贡献),平均年龄范围为 27 至 54 岁)。我们确定了一项正在进行的研究和三项等待分类的研究。一项研究进行了叙述性综合,另一项研究涉及特定的哮喘-COPD 重叠。大多数方案都是基于门诊的,持续三到四周(住院)或八到十二周(门诊)。教育或自我管理部分包括呼吸训练和放松、营养建议和心理辅导。一项方案专门针对严重哮喘患者。与常规护理相比,肺康复可能会增加哮喘患者在完成方案后的最大摄氧量(VO max),但基于 mL/kg/min(两组之间的差异为 3.63 mL/kg/min,95%置信区间(CI)为 1.48 至 5.77;3 项研究;n = 129)和基于 %预测 VO max(差异为 14.88%,95%CI 为 9.66 至 20.1%;2 项研究;n = 60)的研究数据存在非常不确定的证据。与常规护理相比,肺康复对增量穿梭步行试验距离(两组之间的差异为 74.0 米,95%CI 为 26.4 至 121.4;1 项研究;n = 30)的影响存在非常不确定的证据。在更长时间的随访(9 至 12 个月)中,肺康复可能对 VO max 几乎没有影响,但证据非常不确定(MD -0.69 mL/kg/min,95%CI -4.79 至 3.42;I = 49%;3 项研究;n = 66)。肺康复可能会改善哮喘患者的功能性运动能力,6 分钟步行距离的组间差异为 79.8 米(95%CI 为 66.5 至 93.1;5 项研究;n = 529;中等确定性证据)。这种平均变化程度超过了慢性呼吸系统疾病患者的最小临床重要差异(MCID)阈值。关于肺康复对该结局一年后(MD 52.29 米,95%CI 为 0.7 至 103.88;2 项研究;n = 42)的长期影响,证据非常不确定。与常规护理相比,肺康复可能会导致哮喘控制的微小改善,如哮喘控制问卷(ACQ)所示,两组之间的差异为 -0.46(95%CI 为 -0.76 至 -0.17;2 项研究;n = 93;低确定性证据);然而,来自哮喘控制测试的数据非常不确定(两组之间的差异为 3.34,95%CI 为 -2.32 至 9.01;2 项研究;n = 442)。ACQ 发现接近 0.5 点的 MCID。肺康复在 9 至 12 个月的随访中对哮喘控制的影响(MD 0.09,95%CI 为 -0.35 至 0.53;2 项研究;n = 48;低确定性证据)几乎没有差异。肺康复可能会导致哮喘患者生活质量的大幅改善,以圣乔治呼吸问卷(SGRQ)总分为衡量标准(MD -18.51,95%CI -20.77 至 -16.25;2 项研究;n = 440;中等确定性证据),这种变化程度超过了 MCID。然而,肺康复对哮喘生活质量问卷(AQLQ)总分的影响可能很小,证据非常不确定(MD 0.87,95%CI 为 -0.13 至 1.86;2 项研究;n = 442)。更长时间的随访数据表明,肺康复可能会导致生活质量的改善,如 SGRQ 所示(MD -13.4,95%CI 为 -15.93 至 -10.88;2 项研究;n = 430),但不是 AQLQ(MD 0.58,95%CI 为 -0.23 至 1.38;2 项研究;n = 435);然而,证据非常不确定。一项研究报告称,在干预期间,两组之间没有参与者发生哮喘恶化的比例存在差异。来自一项研究的数据表明,与干预相关的不良事件很少发生。总体偏倚风险最常见的是归因于对干预知识的参与者盲法造成的执行偏倚。这在康复研究中是很难克服的。
中度确定性证据表明,肺康复可能与哮喘成人在完成方案后的功能性运动能力和生活质量的临床相关改善相关。最大运动能力的证据确定性为低至非常低。肺康复似乎对哮喘控制的影响很小,尽管证据的确定性很低到非常低。研究方法报告不明确和样本量小限制了我们对整体证据的确定性,而研究设计和干预措施的异质性可能导致不同的临床结局和研究结果不一致。仍有很大的研究空间。